Anixa Capex To Revenue from 2010 to 2024

ANIX Stock  USD 3.32  0.10  3.11%   
Anixa Biosciences Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue is likely to outpace its year average in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.63
Current Value
0.66
Quarterly Volatility
0.33502475
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anixa Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anixa Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 216.9 K, Selling General Administrative of 4.2 M or Total Revenue of 229.4 K, as well as many indicators such as Price To Sales Ratio of 861, Dividend Yield of 0.0 or PTB Ratio of 4.39. Anixa financial statements analysis is a perfect complement when working with Anixa Biosciences Valuation or Volatility modules.
  
Check out the analysis of Anixa Biosciences Correlation against competitors.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Latest Anixa Biosciences' Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Anixa Biosciences over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Anixa Biosciences' Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anixa Biosciences' overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Anixa Capex To Revenue Regression Statistics

Arithmetic Mean0.36
Geometric Mean0.08
Coefficient Of Variation92.42
Mean Deviation0.32
Median0.49
Standard Deviation0.34
Sample Variance0.11
Range0.7001
R-Value0.84
Mean Square Error0.04
R-Squared0.71
Significance0.00008
Slope0.06
Total Sum of Squares1.57

Anixa Capex To Revenue History

2024 0.66
2023 0.63
2018 0.7
2017 0.0345
2016 0.0833
2015 0.49
2014 0.005919

About Anixa Biosciences Financial Statements

Anixa Biosciences investors use historical fundamental indicators, such as Anixa Biosciences' Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Anixa Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.63  0.66 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.